Butler J, Shah SJ, Petrie MC, Borlaug BA, Abildstrm SZ, Davies MJ, Hovingh GK, Kitzman DW, Mller DV, Verma S, Einfeldt MN, Lindegaard ML, Rasmussen S, Abhayaratna W, Ahmed FZ, Ben-Gal T, Chopra V, Ezekowitz JA, Fu M, Ito H et al (2024) Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials
Shree Maruti Pharma is one of Trade India's verified and trusted sellers of listed products
Treatment with semaglutide tablets 14 mg once daily for 26 weeks resulted in a statistically significant reduction in HbA1c from baseline compared to placebo (see Table 8)
Keywords: Basal insulin, GLP-1, Glycaemic control, Network meta-analysis, Semaglutide, Systematic review, Type 2 diabetes Key Summary Points Digital Features This article is published with digital features, including a summary slide, to facilitate understanding of the article
On average, this dual action may lead to greater weight loss and improved blood-sugar outcomes for some people